FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 216 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Breaking down the new standards for cancer care proposed by NHS... March 11, 2022 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 El cáncer en mi comunidad: Cómo superar las desigualdades en la... January 3, 2023 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Load more HOT NEWS Grief Anniversaries Cancer in My Community: How People With Cancer Access Care in... Adding More Mushrooms to Your Diet May Decrease Your Risk of... Study Shows Thymic Health is Linked to Cancer Patients’ Response to...
